SYDNEY, AU, Feb 3, 2023 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award, said the number of cell & gene therapy trials in the region was growing 50% faster than ROW. The majority of... » read more
SYDNEY, AU, Sep 15, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Cell & Gene Therapy Clinical Trials award at the 6th Cell & Gene Therapy World Asia 2022 conference. Novotech has extensive experience in cell & gene therapy clinical trials across Asia Pacific.... » read more
MADISON, WI, Jul 27, 2022 – (JCN Newswire via SEAPRWire.com) – UW Health has selected Hitachi, Ltd. (TSE:6501, “Hitachi”) to provide the infrastructure to support proton therapy at UW Health Eastpark Medical Center. Proton therapy equipment combined with Hitachi’s 360° rotating gantry and Leo’s upright system Hitachi will provide equipment and technology to support UW... » read more
TOKYO, Feb 2, 2022 – (JCN Newswire via SEAPRWire.com) – Hitachi, Ltd. (TSE: 6501) has announced that “Shonan Kamakura Advanced Medical Center” at Shonan Kamakura General Hospital of Tokushukai Medical Group, where Hitachi’s compact proton therapy system (hereafter, “the system”) has been installed, has commenced treatment with the system on 31 January 2022. This is... » read more
TOKYO, Nov 22, 2021 – (JCN Newswire via SEAPRWire.com) – Hitachi, Ltd. (TSE: 6501) announced today that it has been selected by the University of Tsukuba to provide Hitachi’s proton therapy solution including its design, manufacturing, construction, maintenance and operation as a PFI (Private Finance Initiative) project*. The parties have signed the contract on September... » read more
SYDNEY, Oct 14, 2021 – (ACN Newswire via SEAPRWire.com) – Topelia Australia, a biotech company established to commercialise a novel ATT treatment for Australians in quarantine, has launched an investment program designed to keep the invention Australian owned – while rolling out treatment to the world. Prof Thomas Borody – Topelia announces US$25 mil Series... » read more
TOKYO, Jun 24, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer’s disease (AD). Breakthrough Therapy designation is an FDA program... » read more